Source Feed: The Globe and Mail
Author: Kristy Kirkup
Publication Date: October 24, 2025 - 05:00
Family of teen who died after waiting hours for medical care meets Ontario Health Minister
October 24, 2025
The family of an Ontario teen who died after waiting hours to receive care at a hospital say a Thursday meeting with the province’s Health Minister is a good step in their push for legislative change that includes standardized maximum ER wait times for vulnerable pediatric patients.
Hazel and GJ van der Werken, the parents of 16-year-old Finlay van der Werken who died in 2024 of sepsis and pneumonia after he waited for care at an Oakville, Ont., hospital, said they felt heard by Health Minister Sylvia Jones when they discussed their call for legislation entitled “Finlay’s Law.”
Unpublished Newswire
Doctors are calling on provinces to bolster addiction treatment services in response to growing opioid use among young people, a crisis they fear will escalate for decades to come if immediate action is not taken.In a Canadian Medical Association Journal (CMAJ) editorial published Monday, physicians Shannon Charlebois and Shawn Kelly say the escalation of opioid use among youth is being overlooked. Existing addiction services, they say, are also inadequate to meet the needs of young people with opioid use disorder, or OUD.
October 27, 2025 - 00:01 | Alanna Smith | The Globe and Mail
The Alberta government is expected to introduce back-to-work legislation on Monday to force striking teachers to return to classrooms after three weeks, raising fears among labour advocates that the province will invoke the Charter’s notwithstanding clause to override workers’ rights. More than 750,000 students have been out of class since Oct. 6, after negotiations between the Alberta Teachers’ Association and the province broke down.
October 26, 2025 - 21:24 | Meera Raman | The Globe and Mail
Health Canada has for the first time approved a disease-modifying drug for Alzheimer’s disease, a watershed moment that offers hope for patients but does not guarantee that the complex and expensive intravenous therapy will be widely available in this country. The federal regulator on Friday granted a conditional authorization for lecanemab, an antibody drug that can slow the progression of the disease for some people with mild cognitive impairment or early-stage dementia owing to Alzheimer’s.
October 26, 2025 - 21:08 | Kelly Grant | The Globe and Mail
Comments
Be the first to comment